|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600R-mutant melanoma accounts for a significant number of cases even in single-institution practices.
|
31305324 |
2020 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours.
|
31727009 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The history of melanoma prompted molecular analysis, and the lesion was found to harbor the BRAF V600K mutation, consistent with metastatic dedifferentiated melanoma.
|
30562218 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Management of V600E and V600K BRAF-Mutant Melanoma.
|
31741065 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations.
|
31277584 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus.
|
29152725 |
2019 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Eligible participants were adult patients (aged ≥18 years) with histologically or cytologically confirmed surgically resectable clinical stage III or oligometastatic stage IV BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> (ie, Val600Glu or Val600Lys)-mutated melanoma.
|
29361468 |
2018 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
PLA2G6 rs132985*T was associated with BRAF V600E (OR = 1.32, 95% CI = 1.05-1.67) and BRAF other (OR = 1.82, 95% CI = 1.11-2.98), but not BRAF V600K or NRAS+ melanoma.
|
29753029 |
2018 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
If confirmed using larger numbers of V600K tumors, our results may prove useful for designing clinical management and targeted chemotherapeutical interventions for BRAF V600K-positive melanomas.
|
28858076 |
2017 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These results support distinct etiologies for BRAF V600E, BRAF V600K, NRAS<sup>+</sup>, and wild-type melanomas.
|
28842324 |
2017 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
|
27219630 |
2016 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
|
26633701 |
2016 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In total, 88 patients (54%) had BRAFm melanoma (V600E/V600K).
|
26659191 |
2016 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Practical performance assessment employed 33 independent tissue samples, composed of 27 leukemias (by pyrosequencing: 8 wild-type; 18 mutated; 1 noninformative) and 6 melanomas (V600E; V600K; wild-type, 2 each).
|
25611237 |
2016 |
|
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
|
25656898 |
2015 |
|
rs121913227
|
|
melanoma
|
CT |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31).
|
23651150 |
2014 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia.
|
24589925 |
2014 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600K, V600Q, and V600R BRAF melanomas did not positively stain with VE1.
|
24917033 |
2014 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V600E) melanoma in univariate and multivariate analyses.
|
24918823 |
2014 |
|
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
|
rs121913227
|
|
melanoma
|
TT |
0.800 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121913227
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |